GlassScriptPhysician profile
Janelle Kay Hoaglund
NPI 1104459338
$23,882.76
in general payments reported to CMS, 2019-2025
17 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $1,345 · 2023: $11K · 2024: $11K · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $3,537 · Food and Beverage: $3,199 · Consulting Fee: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,740.00 |
| Travel and Lodging | $3,537.15 |
| Food and Beverage | $3,199.00 |
| Consulting Fee | $855.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16,524.05 | 2021-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $4,227.83 | 2022-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $902.05 | 2022-2024 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $670.11 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $381.35 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $332.13 | 2022-2024 | Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $278.93 | 2021-2022 | |
| Corium, LLC | $135.45 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $113.33 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $75.03 | 2024 | Cobenfy |
| Lilly USA, LLC | $55.10 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Lundbeck LLC | $49.44 | 2021-2024 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.39 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.58 | 2023 | Uzedy |
| Indivior INC. | $23.98 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $19.95 | 2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $16.06 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Hoaglund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.